Floatz logo

Ropidoxuridine

Stage III Gastric Cancer AJCC v7

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

282 Active assets in the Stage III Gastric Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

Ropidoxuridine is also rated in:

IDH-wildtype glioblastomaDormant
CC
Indicative ·
47 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CC
Indicative ·
41 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →